Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIALIZE China: SZC for Pre-Dialysis Hyperkalaemia in Chinese Hemodialysis Patients
NCT04217590Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2020
- Primary completion
- Jan 2022
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hyperkalemia comparing Sodium Zirconium Cyclosilicate with Placebo (2 arms). Primary endpoint: Percentage of Responders at 4 weeks. Started Nov 2020; status: completed.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on NCT04217590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04217590.